In terms of R&D for innovative medicines, we have a mature biologics R&D platform for monoclonal antibodies and recombinant protein. Utilising the platform, we have launched (i) Recombinant Human Chorigonadotropin alfa for Injection, followed by (ii) our COVID-19 vaccine “V-01” had obtained the approval for emergency use for heterologous booster vaccination in China, and (iii) we had submitted BLA of our IL-6R mAb.